Exact Sciences Corporation (EXAS) Stock Analysis
DELISTED 2026
What happened to Exact Sciences Corporation (EXAS) stock?
Exact Sciences Corporation (EXAS) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- March 2026
- Last recorded price (historical):
- $104.91 (last quote on record before the March 2026 delisting; historical, not a current quote)
Market cap $20.0B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Exact Sciences Corporation (EXAS). Exact Sciences Corporation specializes in cancer screening and diagnostic tests, with a focus on early detection. Their flagship product, Cologuard, is a non-invasive stool-based DNA test for colorectal cancer screening.
Last analyzed: May 10, 2026These figures come from statements filed 13 months ago — the most recent this company has published.
Exact Sciences Corporation (EXAS) Healthcare & Pipeline Overview
More about this archive record
Can I still buy EXAS shares?
No. EXAS stopped trading on public markets in March 2026, so the shares are not available through a broker. Anything you see quoted for EXAS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EXAS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Exact Sciences Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.